We write for mainstream adults figuring out peptides for the first time. No biohacker jargon. No protocol lists. Just the honest tradeoffs, the real risks, and the named sources.
We've been running the same 11-signal rubric against every GLP-1 telehealth and pharmacy operator we could find. 77 vendors across 19 regions, scored on the same axes. The pattern that emerged was not what we expected.
Tirzepatide has been the most-asked-about drug in the Panya inbox for two years. Here's the entire blog catalog on it, organized by the question you're actually trying to answer.
Semaglutide is sold under four brand names with three different routes of administration and shifting region-by-region availability. Here's the complete index of Panya coverage, organized by what you're trying to figure out.
Bangkok is the lowest-friction GLP-1 access point in Asia for English-speaking adults. Here's the complete map: which clinics actually fill scripts for foreigners, what they charge, what to bring, what to expect.
Our public rubric, current as of May 2026. Each of the 11 signals scored 0 to 100, with what a low/mid/high band looks like in practice. The same rubric on every /vendor scorecard, no exceptions.
BPC-157 is the most-asked-about peptide on the internet right now. Real animal data, almost no human data, a market full of vendors making big claims. Here's the honest version.
GHK-Cu is the rare peptide where the skin-care evidence is real, the hair claims are partial, and the injection protocols are mostly guesswork. Here's how to think about it.
Three drugs are about to change the GLP-1 conversation again. Orforglipron just got FDA approval. CagriSema is in phase 3 readouts. MariTide is the longer-tail bet. Here's the honest read on which deserves your patience and which is hype.
A friend just starting peptides got a three-in-one vial in the mail. The label looked sketchy at first glance. Then the actual data showed something different. The lesson is what changes when you stop trusting the photo.
Most coverage of tirzepatide treats it as a weight-loss drug. For T2D patients, the dose ramp, dosing goal, comparison frame, and what success looks like are all different.
Lifting consistently while on tirzepatide is the single most actionable thing you can do for body composition outcomes. Specific exercises, sets, frequency, and timing relative to dose.
Buying peptides online is harder than it looks. The market is full of vendors making big claims and shipping mixed-quality product. Here's the actual landscape, the red flags, and what verified vendors look like.
We've been running the same 11-signal rubric against every GLP-1 telehealth and pharmacy operator we could find. 77 vendors across 19 regions, scored on the same axes. The pattern that emerged was not what we expected.
Bangkok is the lowest-friction GLP-1 access point in Asia for English-speaking adults. Here's the complete map: which clinics actually fill scripts for foreigners, what they charge, what to bring, what to expect.
The real Bangkok price spread for brand Mounjaro and compounded tirzepatide as of May 2026, ranked from cheapest to most expensive, with the consultation fees and delivery options that change the math.
The peptide market splits into licensed pharmaceutical, licensed compounded, and research-chemical-flavored compounded. The middle category has wide quality variance. Here's how to actually tell them apart.
The scale tells you weight. DEXA tells you what you're actually losing. The patterns at 3, 6, and 12 months on tirzepatide are more nuanced than the trial averages suggest.
The UAE GLP-1 market splits between Dubai's larger and more expat-oriented private clinic ecosystem and Abu Dhabi's more institutionally-driven hospital network. Both work. The right choice depends on your insurance, residence, and what you're actually trying to achieve.
Most first-visit conversations get rushed because the patient isn't prepared and the clinician has 12 minutes. Here's the prep list that makes the appointment actually useful.
The most-quoted patient experience on tirzepatide is that the food noise stops. Here's what people mean by it, what's actually happening neurologically, and why it doesn't return for everyone after stopping.
Rapid weight loss is associated with bone density changes. The GLP-1 trial data on bone is more nuanced than the headlines suggest. Here's what's known, what's contested, and what to do about it.
Rapid weight loss can shift kidney function metrics in ways that look concerning but usually aren't. Here's what to track, what's normal, and when the labs mean something.
The mental health conversation around GLP-1s has gotten louder in the last year. Some of the signal is real and worth taking seriously. Some is noise. Here's the honest separation.
GLP-1s slow gastric emptying, which slows gallbladder contraction, which can produce stasis and stones. The counterintuitive prevention involves more fat, not less.
Supply gaps happen. Pen recalls, pharmacy shortages, prescription delays, travel disruptions. Most patients don't have a plan until the gap is already happening. Here's the framework.
The London private GLP-1 market has fragmented since the NHS Wegovy expansion in late 2025. Here's the current operational state of who's prescribing, what they charge, and which path is wrong for whom.
The window for catching a missed weekly dose is wider than most patient handouts say. Here's what actually matters and how to think about getting back on cycle.
Semaglutide is sold under four brand names with three different routes of administration and shifting region-by-region availability. Here's the complete index of Panya coverage, organized by what you're trying to figure out.
Singapore is more expensive but more predictable. Bangkok is cheaper but more variable. The right choice depends on your trip length, risk tolerance, and whether you're optimizing for a single visit or a relationship.
The two main expat-clinic neighborhoods in Bangkok have different operator profiles for GLP-1 access. Sukhumvit is denser and more international; Silom is more business-oriented and slightly cheaper. Both work.
Most clinics either keep you at maintenance dose forever or have you stop cold turkey. The middle path, a structured taper, is more workable than either, but the protocol isn't standardized. Here's what's known.
Rapid weight loss can trigger gout flares in patients prone to them. The mechanism is well-understood, the pattern is predictable, and the prevention is mostly straightforward.
Sleep changes on tirzepatide are real and patterned. Some are good (apnea improvement is well-documented), some are mixed (lighter sleep early on), some are bad if you ignore them. Here's the full picture.
Anesthesiologists are now routinely asking about GLP-1 use before procedures. The reason is real, the timing matters, and the conversation often happens too late if you don't bring it up first.
Tirzepatide has been the most-asked-about drug in the Panya inbox for two years. Here's the entire blog catalog on it, organized by the question you're actually trying to answer.
Constipation is the second most common tirzepatide side effect after nausea, and unlike nausea it doesn't fade on its own. Here's the protocol that actually works.
Tirzepatide is contraindicated in pregnancy, but the timing question is more nuanced than 'stop when you decide to try.' Here's the protocol most prescribers use, and why it usually doesn't get explained at the appointment.
Local rash at the injection site is one of the more common but rarely-discussed tirzepatide side effects. Most cases are minor and resolve. The few that don't follow a predictable pattern.
Pen technique gets twenty seconds at the prescription appointment. The patient handouts say 'rotate sites'. There's more to it, and a few of the details affect whether week one is rough or smooth.
Most prescribers don't order routine labs on tirzepatide unless something goes wrong. Here's the panel worth requesting at baseline, six months, and twelve months even when nothing has gone wrong.
About 15-20% of patients respond poorly to tirzepatide. Most cases are workflow problems with fixable causes. Here's the diagnostic decision tree.
The pancreatitis warning on GLP-1s has been around since the early days of the class. The accumulated evidence after 8 years of widespread use is more reassuring than the warning suggests, but the patient-level decision still has nuance.
Most clinics tell you to 'eat more protein' on tirzepatide. The number you actually need is higher than baseline guidelines suggest, and the timing matters more than the total.
Every tirzepatide prescription carries an FDA boxed warning about thyroid C-cell tumors. The data behind the warning is more specific than the warning itself, and it matters for who actually shouldn't take the drug.
What customs actually cares about, how cold chain works in checked luggage, and the documentation that gets you through any border without a problem.
Vendor pricing pages are designed to make decisions easy at the cost of clarity. Here's the patterns that signal you're about to overpay or land at the wrong vendor entirely.
The trial averages on regain mask substantial variance. The patterns that predict who keeps the loss and who doesn't are partly biological and partly behavioral.
Lilly has redesigned the Mounjaro pen multiple times since 2023 and ships region-specific variants. Most pen-appearance changes are legitimate. The few that aren't matter.
Three telehealth operators (Juniper, Pilot, Mosh) plus LillyDirect's direct path. TGA September 2025 advertising enforcement reset the marketing landscape. Brand-pharmacy supply only · Australia doesn't have a US-style compounded GLP-1 market. Per-month pricing, what each operator actually offers, who fits where.
I keep getting the same question from different friends in different cities. Here's the version short enough to get through over coffee. The decision today (May 2026) is different from the one a year ago, and the difference is mostly about what you actually want from your supply chain.
A coach in Singapore told me the same thing my doctor friend in Bangkok told me: the people who quit tirzepatide almost all quit between week 6 and week 10. The reason isn't the side effects you'd guess. It's the gap between when the discomfort peaks and when the visible results start showing up.
An afternoon in Sukhumvit, four clinics, the same five questions about Mounjaro at each one. The price quotes ranged from 6,000 to 14,500 baht for the same dose. The medical conversation ranged from 'sign here' to a 30-minute consult. Here's what I learned about how to actually choose.
A friend asked me last week whether to keep paying $179 a month for compounded tirzepatide from her telehealth provider. The honest answer involves the April 30 FDA proposal, the difference between 'still shipping' and 'safe to bet on', and a conversation about what brand pricing looks like once she does the math on insurance.
Most coverage is either too dismissive (\"just some nausea\") or too alarmist (\"brutal stomach issues forever\"). After watching a few hundred people start tirzepatide and semaglutide over the past year, here's the actual shape of the side effects most people get.
A reader sent me a denial letter from her US insurer. They covered Wegovy. They didn't cover Mounjaro. Same patient, same diagnosis, same prescriber. The reason isn't medical. It's a contract that nobody mentions.
A clinic in Bangkok used the phrase 'maintenance dose' three times in one consultation without ever defining it. The patient nodded each time. Then she asked me afterwards what it meant. The honest answer is that nobody knows for sure yet, but here's what we're learning.
Eli Lilly launched Mounjaro in NZ February 2026 via Medsafe approval; private telehealth (Well Revolution + Pocket Lab) stocking from launch week. Wegovy still pending Medsafe filing. Foundayo (orforglipron) MHRA / EMA / Medsafe trajectory all 12-18 months behind FDA. What NZ readers can do today.
Almost every patient on tirzepatide hits a stretch around month five or six where the scale stops moving for two or three weeks. The instinct is to push the dose higher. The instinct is usually wrong.
I went through the homepage of a vendor a friend was about to buy from and counted 11 marketing tells in the first scroll. Here's what those tells look like and what to look for instead. The skill takes 90 seconds per site once you know what you're looking at.
Almost all the public conversation about tirzepatide is about the first six months. The trial data, the dramatic before-and-afters, the side-effects window. The second year is where the harder questions live: maintenance dose, plateau, lean mass, and the question nobody asks until they're in it.
It's the most-asked question in the GLP-1 conversation and the answer most articles give is some version of 'tirzepatide loses more weight, choose tirzepatide if you can.' That's directionally true and practically incomplete. Here's the version that actually helps you decide.
MOH Circular 87/2024 hit its one-year anniversary in March; the in-person-consultation rule is now observable, not theoretical. Foundayo (orforglipron) HSA pathway tracking 12-18 months behind FDA. Oral Wegovy 25mg HSA filing the more imminent question. What changed for SG readers since the April buyer's guide.
Three or four glasses of wine used to feel fine. On tirzepatide, two leaves you flat for a day. The interaction isn't dangerous in any acute sense for most people, but it's real and it's worth understanding before your next dinner out.
The Australian regulator added a contraception note to the tirzepatide label in late 2025. The effect they're flagging is real but narrower than the headlines suggested. If you're on combined oral contraceptives, here's what to actually do.
If the medication is already suppressing your appetite, do you get extra benefit from skipping breakfast on top of it? The honest answer surprised me when I started looking at it carefully.
Rapid weight loss is a known risk factor for gallstone formation. Tirzepatide produces rapid weight loss. The math is straightforward. The clinical signals you need to know about and the things that meaningfully reduce risk are less straightforward.
Hair shedding around month three or four catches a lot of people off guard. It's one of the more underdiscussed parts of the GLP-1 experience. The good news: it's almost always temporary. The actionable news: there are three things that meaningfully help.
Tirzepatide isn't recommended in pregnancy. The reasons matter. The pause-before-trying timeline matters more. The conversations about this are usually rushed, often during a brief appointment, and they leave women holding the harder questions alone.
What changed for UK GLP-1 access since the April 2026 buyer's guide. NHS QOF tirzepatide indicators went live April 1; Cohort 2 (BMI 35-39.9) starts June; oral Wegovy 25mg shipped at private pharmacies in January; Foundayo (orforglipron) MHRA pathway tracked. Private market still dominant. What to do today.
A reader sent me a DM at 11pm on a Sunday: appointment Monday morning, what do I actually need to ask? The list most people Google online is too long, vague, and written by someone who has never had a 15-minute appointment. Here's the shorter list that matters.
A reader at month 12 asked me what happens if she stops. The honest answer involves the trial data on weight regain, the lifestyle changes that determine how much, and a more useful frame: stopping isn't a single event, it's a process that takes about as long as starting did.
A friend got scheduled for elective surgery and her surgeon told her to pause tirzepatide for a week before. Her telehealth provider had no idea this was a thing. The list of reasons to pause is longer than most providers acknowledge, and pausing is mostly fine.
Resmetirom is the only approved MASH drug today. Survodutide just read out phase 3 obesity at 16.6%; LIVERAGE + LIVERAGE-Cirrhosis pending. Pemvidutide IMPACT-MASH starting phase 3 H2 2026. Why we hold on MASH-specific routing recommendations and what we'd need to see to start.
Eight US telehealth platforms scored against Panya's 11-signal rubric. Three routable (Ro, Calibrate, WW Clinic), one conditional (Found), four hold (Hims, Mochi, Henry, Eden). The April 30 FDA proposal closes the cheap-compounded-supply lane · this is the new map.
The patient handouts give you a list of possible side effects. They don't tell you the timeline. Here's the day-by-day version most clinics don't write down.
The most common reader question I get from people who train regularly is whether tirzepatide will tank their lifts. The honest answer is more interesting than yes or no.
Microdosing GLP-1 went from a fringe biohacker idea to a question people ask their doctor. The clinical data is thinner than the discourse suggests, but it's not nothing. Here's what's known.
The mistake most people make on the switch is treating it like upgrading a phone. The drugs work on different receptor mixes and the body needs a beat to recalibrate. Here's how to do it without the rebound.
Most clinic intake forms are designed to qualify you for a prescription, not to qualify the clinic for your trust. Here's the inversion: the questions that separate a careful supplier from a cargo-cult one.
Five months after the FDA closed enforcement discretion on 503A and 503B compounded tirzepatide and semaglutide, the US compounded-GLP-1 landscape has consolidated, contracted, and fragmented. The April 30 scorecard recap captured the snapshot. This is what changed in the four weeks after.
BPOM intermittency means the existing Bali buyers guide gets stale fast. This is the May 2026 supply-state tactical · per-clinic Mounjaro and Ozempic stocking, the most-current expat-routable picks, and the Bangkok-hop fallback when the nomad-clinic layer has gaps.
Bangkok is the regional anchor for legitimately-supplied tirzepatide and semaglutide in Southeast Asia. Flight matrices, clinic-relationship cadence, cold-chain transit, customs personal-use rules per origin country, and the four-versus-twelve-week supply math.
Weekly read on what's actually in stock at the Bangkok premium hospitals and mid-tier clinics, with price changes since last digest, regulatory movements that affect supply, and the picking question for this week. New format, weekly cadence, BKK-anchored. Issue 1.
The semaglutide and tirzepatide effect on alcohol intake is real and well-documented. The mechanism is partly understood, the long-term safety data is thin, and the practical advice for users on the drug is more nuanced than 'one drink is fine.' What the 2026 SURMOUNT-OASIS and downstream trials add.
HK Department of Health licenses Wegovy + Mounjaro for limited indications. Private clinic supply is steady but premium-priced. The 1h45 Bangkok flight is the cost-arbitrage many HK-resident expats end up using. What's actually licensed, per-clinic pricing, and the picking framework.
A short guide to the seven things on every /vendor/<id> page. The score, the verdict, the per-signal bands, the channel description, the regulatory citations, and the visit-or-hold CTA. What each piece means and what to do with it.
What actually shifted in the last 60 days: Foundayo (orforglipron) approved early under the National Priority Voucher, oral Wegovy 25mg shipping, FDA proposes excluding tirzepatide from 503B bulks, RFK pulled 14 peptides off Category 2, survodutide phase 3 obesity readout. Routing impact for each.
Eli Lilly's triple agonist (GLP-1 + GIP + glucagon) has TRIUMPH-1, TRIUMPH-2, and TRIUMPH-4 readouts in the public record. Weight reduction at 12mg lands above tirzepatide. Cardiovascular signal is being watched. FDA filing window now points at late 2026. What this changes in routing decisions today.
The Singapore GLP-1 clinic layer beyond the existing buyers guide. Per-clinic pricing for the four most-routable Singapore providers, MOH-licensed-product reality, the Wegovy-vs-Ozempic supply picture, and when the 2h20 Bangkok flight beats the local cost.
The dose-step decisions most people get wrong on tirzepatide. When to stay at 5mg, when to push to 10mg, what gastrointestinal side effects actually tell you, and the muscle-loss + protein math nobody mentions until it bites.
Pure Rawz, Limitless Life Nootropics, Amino Asylum, Empower Pharmacy, and Strive Pharmacy scored on Panya's public 11-signal rubric. The headline finding: Amino Asylum is offline after a June 2025 FDA enforcement action. The compounders carry active regulatory weight. The research-chem channel has structural ceilings that the COA cannot fix.
The four most-routable Vietnam clinics for GLP-1 prescribing scored against the 11-signal rubric. FV Hospital (HCMC), Family Medical Practice (HCMC + Hanoi), Raffles Medical (HCMC), Vinmec (multi-city). Saxenda pricing, MoH posture, and the Bangkok-hop framing for the gap.
Side-by-side comparison of the three branded GLP-1 pens available in Bangkok in May 2026. Per-month USD pricing at premium hospitals and mid-tier clinics, supply state per medication, and the picking question once cost is on the table.
The Panya catalog scores 60+ vendors on the 11-signal rubric. Some land in routable, some in conditional, some in hold. The hold-verdict scorecards are the most useful pages we publish · here is why we keep them and what they do for the people who land on them.
The 11-signal rubric is public. The audits behind every score are run by humans + agents. Both make mistakes. This is the running list of scoring calls we got wrong, what we corrected, and what the editorial process changes in response.
Retatrutide, orforglipron, CagriSema, survodutide, MariTide, pemvidutide. Where each one sits in phase 3, the readout window, the mechanism, and what each approval would shift for routing decisions today. Bleeding edge of the science, conservative on the rating.
The four Bangkok premium hospitals scored on Panya's 11-signal rubric: Bumrungrad, Samitivej Sukhumvit, BNH, and BDMS Wellness Clinic. JCI accreditation, real GLP-1 menu depth, BDMS-group concentration, and how Thailand-resident expats actually pick.
BIMC Hospital, Body Tonic Clinic, Cocoon Medical Spa, Siloam, Kasih Ibu. USD pricing, BPOM posture post-2025 import tightening, and how nomads + expats actually pick a Bali GLP-1 provider.
Chi Longevity, The Longevity GP, Siena Health, Noah, Ordinary Folk, Clifford Clinic. SGD pricing, MOH 87/2024 in-person-first rule, what the 11-signal rubric scores them on, and how expats actually pick.
Metabolic.Health, Endocare, Zone.Health, DarDoc, Valeo, Limitless Human, Hortman, Novomed. AED pricing, DHA / DOH posture, Foundayo arrival, and how to pick the right Emirates GLP-1 route.
Numan, Voy, Juniper, Boots, Asda, Pharmacy2U, ZAVA, Second Nature. Per-dose pricing, MHRA posture, what the rubric scores them on, and how to pick the right one for your situation.
FV Hospital, Family Medical Practice, Raffles Medical, Vinmec. USD pricing, MoH posture, supply intermittency reality, and how expats actually pick a Vietnam GLP-1 provider.
A working guide to Bangkok's longevity clinic landscape for expats: which clinics have real diagnostic depth, which ones rent the aesthetic, what the price bands look like, and how to tell them apart.
The real differences between compounded tirzepatide from a 503A pharmacy and brand Mounjaro from Eli Lilly. Regulatory status, quality control, pricing, and when one is clearly better than the other.
Longevity clinics are prescribing tirzepatide and semaglutide at fractional doses for non-obese patients. Here is what the data supports, what it does not, and the risk-benefit tradeoff.
US employer health plans often exclude weight-loss medication even when they cover Type 2 diabetes. Here is why the coverage gap exists, how to check your specific plan, and the legitimate workarounds.
Retatrutide hits three receptors instead of two. Phase 2 showed 24% weight loss. Phase 3 results expected late 2026. What it is, how it differs from tirzepatide, and why the molecule matters.
The three GLP-1 drugs that matter in 2026: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide (Lilly's triple-agonist). How they differ in mechanism, weight loss, side effects, and cost.
Eight physical tells on a real Eli Lilly Mounjaro pen, what counterfeiters get wrong, and how to sanity-check a vial or pen from any source before you inject. Updated April 2026.
The SURMOUNT-4 trial tracked what happens when people stop tirzepatide after initial weight loss. Here is the honest version of the regain curve, what drives it, and how to think about maintenance.
GLP-1 drugs including tirzepatide reduce alcohol consumption for many users. Here is the mechanism, the observational data, the clinical caution, and how Panya routes patients who mention drinking on intake.
ราคา tirzepatide ในกรุงเทพปี 2026 คลินิกแบรนด์และผู้ขายตรง ช่วงราคาจริง วิธีเลือกคลินิกที่น่าเชื่อถือ และสิ่งที่ควรถามก่อนเริ่ม
Tirzepatide monthly cost across 10 markets: US brand, US compounded, UK private, Scandinavia, Germany, Thailand clinic, Thailand direct, Japan, Singapore, Australia. The real numbers, updated April 2026.
The week-by-week tirzepatide dose schedule from 2.5 mg to 15 mg, why the ramp exists, what clinics skip, and when to plateau. SURMOUNT-1-aligned, clinician-reviewed.
Roughly 25 percent of weight lost on tirzepatide is lean mass unless you intervene. The protein target, training cadence, and supplement stack that preserves muscle during GLP-1 weight loss, per Attia, Norton, and the published data.
Our public rubric, current as of May 2026. Each of the 11 signals scored 0 to 100, with what a low/mid/high band looks like in practice. The same rubric on every /vendor scorecard, no exceptions.
The credentialed clinicians have covered GLP-1 drugs for years. Here is what they actually say, not the clickbait version.
Flight, accommodation, clinic selection, first visit, follow-up, and what to bring home. Written for first-timers.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
Heat degrades peptides. But not all peptides, not at all temperatures, not at all durations. The honest version of the cold-chain question.
The five things that matter on a COA, the three things that do not, and the one question that separates a serious vendor from a cargo-cult operator.
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The tirzepatide weight-loss trial that reset the market. Here is what it tested, what it found, and the parts the press skipped.
What actually happens when you start tirzepatide. What is common, what is rare, what is serious, what to do about each.
What tirzepatide is, what it costs in Bangkok, how to tell a real clinic from a mediocre one, and the questions you should ask before your first injection.
Same drug class, different receptor profile. Here is the honest comparison, without the marketing gloss.
RFK and HHS moved most restricted peptides back to Category 1 in early 2026. Here is what that actually does, and what it does not.
Most peptide comparison sites are really just attack blogs. We do it differently, on purpose. Here is the logic.
Prefer RSS? Subscribe to the feed →